| Budget Amount *help |
¥91,520,000 (Direct Cost: ¥70,400,000、Indirect Cost: ¥21,120,000)
Fiscal Year 2021: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2019: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2017: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to investigate the significance of quantity and quality aspects of organ lipids in the pathophysiology of chronic inflammation, fibrosis and organopathy. We observed that 1) we performed scRNA-seq of pancreatic islets from diabetic mice and identified a new prediabetic marker gene and several beta-cell transdifferentiation pathways; 2) CREB3L3 has multi-potent protective effects against atherosclerosis owing to new mechanistic interaction between CREB3L3 and SREBPs under atherogenic conditions; 3) RHBDL4/RHBDD1, a rhomboid family protease, directly cleaves SREBP-1 at ER and the RHBDL4-SREBP-1c pathway reveals a regulatory system for monitoring fatty acid composition and maintaining cellular lipid homeostasis. Our findings provided evidence supporting the important role of quantity and quality control of organ lipids as a therapeutic target for inflammatory diseases.
|
